Updated:
ProKidney Corp.
A Potential New Era in the Treatment of CKD | ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was...
ProKidney Corp.
A Potential New Era in the Treatment of CKD | ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
General information
Firm type
Asset Manager
Year founded
2015
Location
Region
North America
Country
United States
City
Winston-Salem
Corporate office
Winston-Salem, NC, United States
Principals
Dr. Tim Bertram
Co-Founder and former CEO
Bruce Culleton
Chief Executive Officer
Sector focus
Frequently asked questions
Who leads the executive team at ProKidney?
Bruce Culleton serves as CEO, bringing a clinical background as a nephrologist with prior leadership roles in the kidney-disease industry. Dr. Tim Bertram, the scientific founder and former CEO, originated the core REACT technology through decades of research in regenerative medicine. The executive team is lean, as disclosed in public SEC filings, and is concentrated on advancing the single-product pipeline through regulatory approval.
Does ProKidney have external co-investors or fund commitments alongside its R&D?
No. ProKidney does not operate as a fund manager and does not make co-investments, fund commitments, or club deals. The company is a pure-play operating entity. Its capital structure is funded by equity and debt raised from public markets and private placements, including the proceeds from its 2022 SPAC merger with Social Capital Suvretta Holdings Corp. III.
What is the status of the Phase 3 clinical trial for REACT?
ProKidney's Phase 3 REGEN-003 trial completed enrollment of over 1,500 patients and released topline data in March 2025. The trial studied REACT in patients with moderate to severe diabetic kidney disease, comparing the therapy against standard-of-care conservative management. The release of these results marked the pivotal de-risking event for the company's single-asset pipeline (per the firm's official communications, March 2025).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: